Galdadas, Ioannis http://orcid.org/0000-0003-2136-9723
Lovera, Silvia
Pérez-Hernández, Guillermo
Barnes, Melissa D.
Healy, Jess http://orcid.org/0000-0001-7437-1742
Afsharikho, Hamidreza
Woodford, Neil
Bonomo, Robert A.
Gervasio, Francesco L. http://orcid.org/0000-0003-4831-5039
Haider, Shozeb http://orcid.org/0000-0003-2650-2925
Article History
Received: 28 March 2018
Accepted: 13 August 2018
First Online: 27 August 2018
Competing Interests
: NW: No personal interests to declare. However, PHE’s AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Achaogen Inc, Allecra Antiinfectives GmbH, Amplex, AstraZeneca UK Ltd, Becton Dickinson Diagnostics, The BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, European Centre for Disease Prevention and Control, Food Standards Agency, GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, IHMA Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp, Meiji Seika Pharma Co., Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Shionogi & Co. Ltd, Trius Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd., and the World Health Organization. IG is funded by Astra Zeneca-EPSRC case studentship award to FLG and SH. RB has research grants from Allecra, Entasis Therapeutics, Merck & Co. (Kenilworth, NJ), Roche, and Wockhardt. SL is a postdoc at UCB BioPharma SPRL.